» Articles » PMID: 33308184

Discussing Personalized Prognosis in Amyotrophic Lateral Sclerosis: Development of a Communication Guide

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2020 Dec 14
PMID 33308184
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Personalized ENCALS survival prediction model reliably estimates the personalized prognosis of patients with amyotrophic lateral sclerosis. Concerns were raised on discussing personalized prognosis without causing anxiety and destroying hope. Tailoring communication to patient readiness and patient needs mediates the impact of prognostic disclosure. We developed a communication guide to support physicians in discussing personalized prognosis tailored to individual needs and preferences of people with ALS and their families.

Methods: A multidisciplinary working group of neurologists, rehabilitation physicians, and healthcare researchers A) identified relevant topics for guidance, B) conducted a systematic review on needs of patients regarding prognostic discussion in life-limiting disease, C) drafted recommendations based on evidence and expert opinion, and refined and finalized these recommendations in consensus rounds, based on feedback of an expert advisory panel (patients, family member, ethicist, and spiritual counsellor).

Results: A) Topics identified for guidance were 1) filling in the ENCALS survival model, and interpreting outcomes and uncertainty, and 2) tailoring discussion to individual needs and preferences of patients (information needs, role and needs of family, severe cognitive impairment or frontotemporal dementia, and non-western patients). B) 17 studies were included in the systematic review. C) Consensus procedures on drafted recommendations focused on selection of outcomes, uncertainty about estimated survival, culturally sensitive communication, and lack of decisional capacity. Recommendations for discussing the prognosis include the following: discuss prognosis based on the prognostic groups and their median survival, or, if more precise information is desired, on the interquartile range of the survival probability. Investigate needs and preferences of the patients and their families for prognostic disclosure, regardless of cultural background. If the patient does not want to know their prognosis, with patient permission discuss the prognosis with their family. If the patient is judged to lack decisional capacity, ask the family if they want to discuss the prognosis. Tailor prognostic disclosure step by step, discuss it in terms of time range, and emphasize uncertainty of individual survival time.

Conclusion: This communication guide supports physicians in tailoring discussion of personalized prognosis to the individual needs and preferences of people with ALS and their families.

Citing Articles

Natural Products and Their Neuroprotective Effects in Degenerative Brain Diseases: A Comprehensive Review.

Lim D, Lee J, Lee C, Kim Y Int J Mol Sci. 2024; 25(20).

PMID: 39457003 PMC: 11508681. DOI: 10.3390/ijms252011223.


Prognostic communication in amyotrophic lateral sclerosis: findings from a Nationwide Italian survey.

Moglia C, Palumbo F, Botto R, Iazzolino B, Ticozzi N, Calvo A Neurol Sci. 2024; 45(12):5787-5794.

PMID: 39073531 DOI: 10.1007/s10072-024-07702-6.


The role of statins in amyotrophic lateral sclerosis: protective or not?.

Al-Kuraishy H, Jabir M, Sulaiman G, Mohammed H, Al-Gareeb A, Albuhadily A Front Neurosci. 2024; 18:1422912.

PMID: 38903602 PMC: 11188367. DOI: 10.3389/fnins.2024.1422912.


Accelerating drug development for amyotrophic lateral sclerosis: construction and application of a disease course model using historical placebo group data.

Cai R, Yang J, Wu L, Liu Y, Wang X, Zheng Q Orphanet J Rare Dis. 2024; 19(1):40.

PMID: 38308282 PMC: 10837960. DOI: 10.1186/s13023-024-03057-5.


Serum Neurofilaments in Motor Neuron Disease and Their Utility in Differentiating ALS, PMA and PLS.

McCluskey G, Morrison K, Donaghy C, McConville J, McCarron M, McVerry F Life (Basel). 2023; 13(6).

PMID: 37374084 PMC: 10301889. DOI: 10.3390/life13061301.


References
1.
Borasio G, Sloan R, Pongratz D . Breaking the news in amyotrophic lateral sclerosis. J Neurol Sci. 1998; 160 Suppl 1:S127-33. DOI: 10.1016/s0022-510x(98)00211-1. View

2.
Clayton J, Butow P, Tattersall M . The needs of terminally ill cancer patients versus those of caregivers for information regarding prognosis and end-of-life issues. Cancer. 2005; 103(9):1957-64. DOI: 10.1002/cncr.21010. View

3.
Mitchison D, Butow P, Sze M, Aldridge L, Hui R, Vardy J . Prognostic communication preferences of migrant patients and their relatives. Psychooncology. 2011; 21(5):496-504. DOI: 10.1002/pon.1923. View

4.
Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S . ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018; 91(15):e1370-e1380. PMC: 6177274. DOI: 10.1212/WNL.0000000000006317. View

5.
Andersen P, Abrahams S, Borasio G, de Carvalho M, Chio A, Van Damme P . EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2011; 19(3):360-75. DOI: 10.1111/j.1468-1331.2011.03501.x. View